Manufacturers: Hikma farmaceutica (portugal) sa, Nexus pharmaceuticals inc +12 more
Benzatropine is an anticholinergic drug used to treat Parkinson's disease (PD) and extrapyramidal symptoms, except tardive dyskinesia.
Benzatropine is an anticholinergic drug used to treat Parkinson's disease (PD) and extrapyramidal symptoms, except tardive dyskinesia.
Benztropine is an agent with anti-muscarinic and antihistaminic effects. Its main mechanism of action is presented by the selective inhibition of dopamine transporters but it also presents affinity for histamine and muscarine receptors. It is widely known that benztropine is a potent inhibitor of presynaptic carrier-mediated dopamine transport. As well, it is known to be an analog of atropine and hence, it has a large affinity for muscarinic receptors M1 in the human brain. Once bound, benztropine blocks the activity of the muscarinic receptors mainly in the striatum. The increased advantage of benztropine lays on the antagonism of acetylcholine activity which corrects the imbalance between dopamine and acetylcholine in Parkinson patients.
用于治疗帕金森病。也用于药物引起的锥体外系疾患，口服1小时起效，肌肉或静脉注射数分钟内起效，作用持续24小时。具有抗胆碱及抗组胺作用，并有轻度局部麻醉作用。
1 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
